Author:
Kuznetsov Vladimir,Lee Hwee Kuan,Maurer-Stroh Sebastian,Molnár Maria Judit,Pongor Sandor,Eisenhaber Birgit,Eisenhaber Frank
Abstract
Abstract
Abstract
The currently hyped expectation of personalized medicine is often associated with just achieving the information technology led integration of biomolecular sequencing, expression and histopathological bioimaging data with clinical records at the individual patients’ level as if the significant biomedical conclusions would be its more or less mandatory result. It remains a sad fact that many, if not most biomolecular mechanisms that translate the human genomic information into phenotypes are not known and, thus, most of the molecular and cellular data cannot be interpreted in terms of biomedically relevant conclusions. Whereas the historical trend will certainly be into the general direction of personalized diagnostics and cures, the temperate view suggests that biomedical applications that rely either on the comparison of biomolecular sequences and/or on the already known biomolecular mechanisms have much greater chances to enter clinical practice soon. In addition to considering the general trends, we exemplarily review advances in the area of cancer biomarker discovery, in the clinically relevant characterization of patient-specific viral and bacterial pathogens (with emphasis on drug selection for influenza and enterohemorrhagic E. coli) as well as progress in the automated assessment of histopathological images. As molecular and cellular data analysis will become instrumental for achieving desirable clinical outcomes, the role of bioinformatics and computational biology approaches will dramatically grow.
Author summary
With DNA sequencing and computers becoming increasingly cheap and accessible to the layman, the idea of integrating biomolecular and clinical patient data seems to become a realistic, short-term option that will lead to patient-specific diagnostics and treatment design for many diseases such as cancer, metabolic disorders, inherited conditions, etc. These hyped expectations will fail since many, if not most biomolecular mechanisms that translate the human genomic information into phenotypes are not known yet and, thus, most of the molecular and cellular data collected will not lead to biomedically relevant conclusions. At the same time, less spectacular biomedical applications based on biomolecular sequence comparison and/or known biomolecular mechanisms have the potential to unfold enormous potential for healthcare and public health. Since the analysis of heterogeneous biomolecular data in context with clinical data will be increasingly critical, the role of bioinformatics and computational biology will grow correspondingly in this process.
Publisher
Springer Science and Business Media LLC
Reference119 articles.
1. Eisenhaber F: A decade after the first full human genome sequencing: When will we understand our own genome?. J Bioinformatics Comp Biol. 2012, 10: 12710-
2. The Human Genome Project Completion: Frequently Asked Questions: 3-26-2012 http://www.genome.gov/11006943
3. Sequencing competition heats up: 3-28-2012 http://rna-seqblog.com/news/sequencing-competition-heats-up/
4. Eisenhaber F: Bioinformatics: Mystery, Astrology or Service Technology. Preface. Discovering Biomolecular Mechanisms with Computational Biology. Edited by: Eisenhaber F. 2006, Georgetown: Landes Biosciences and Eurekah.com, 1-10. 1st
5. Bio-IT World 10th Anniversary 2002-2012: 2-8-2012 http://www.bio-itworld.com/10th-Anniversary/
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献